SPINE
2026 SLARD Annual Meeting: Chondrolyase For The Treatment of Pain In Patients With Lumbar Disc Herniation
OrthoEvidence Journal (OE Journal) - ACE Report
Epub Ahead of Print
3 randomized clinical trials including patients with lumbar disc herniation were included in this systematic review and meta-analysis comparing chondroitinase injection vs sham injection. Pooled outcomes of interest included worst leg pain measured on a 100 mm visual analog scale, Oswestry Disability Index (ODI) score, and herniated disc volume. At 13 weeks, chondroitinase significantly reduced worst leg pain, improved disability, and decreased herniated disc volume compared with sham treatment. These findings suggest that chondroitinase may provide symptomatic and structural benefit for patients with lumbar disc herniation who have persistent symptoms despite conservative care.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
